SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency
ZUG, Switzerland–(BUSINESS WIRE)– The Marketing Authorization Application (MAA) for SB5, an adalimumab biosimilar candidate referencing Humira ®1, has been accepted for review by the European...